ZYUS Life Sciences Appoints John Knowles as Interim Chief Financial Officer

10:57 AM EDT, 09/15/2026 (MT Newswires) -- ZYUS Life Sciences (ZYUS.V) said Tuesday that John Knowles, a board member who also chairs the audit committee, has been appointed interim chief financial officer. He takes over from John Hyshka, who has been on an indefinite leave of absence from his position, and is no longer with Zyus, effective Sept. 14. Zyus Life expects to release topline results from its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial at the end of the third quarter or early fourth quarter. The trial is evaluating Trichomylin softgel capsules in patients experiencing moderate to severe cancer-related pain. Pain reduction is one of the primary endpoints of the trial, a statement said. Zyus Life shares last traded on Sept. 14, closing at CA$0.45 on the TSX Venture Exchange.